Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Abemaciclib

An inhibitor of the CDK4 and CDK6 kinases, approved in the United States in 2017 for advanced hormone receptor-positive, HER2-negative breast cancer, both on its own and together with hormone therapy. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?The suffix -ciclib, shared with palbociclib and ribociclib, marks inhibitors of cyclin-dependent kinases, the proteins that give the cell the go-ahead to divide.

AbemaciclibGo to the active ingredient →
AbemaciclibActive ingredientAbemaciclibCat. No. P-A003-001CAS 1231929-97-7
Abemaciclib-d5Isotopically labelledAbemaciclib-d5Cat. No. P-A003-003CAS 1809251-51-1

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.